IDO1 and cancer: Future directions in targeting the kynurenine pathway include the development of dual inhibitors that target both IDO1 and TDO2, as well as the investigation of combination therapies that include metabolic inhibitors, ROS inducers, and other agents that disrupt cancer metabolism.